4.5. Kết quả xác định mối liên quan giữa đa hình Arg399Gln với nguy cơ mắc bệnh lupus ban đỏ hệ thống
DỰ KIẾN KẾT LUẬN
liên kết. Bệnh học cơ xương khớp nội khoa. NXB giáo dục Việt Nam, 49–71. 2. Bộ Y Tế (2016). Hướng dẫn chẩn đoán và điều trị các bệnh cơ xương khớp
(Ban hành kèm theo Quyết định số 361/QĐ-BYT Ngày 25 tháng 01 năm 2014 của Bộ trưởng Bộ Y tế), Nhà xuất bản Y học.
3. Wallace D.J. (2014). Lupus: the essential clinician’s guide, Oxford University Press, Oxford ; New York.
4. Boodhoo K.D., Liu S., and Zuo X. (2016). Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Medicine, 95(29), e4272.
5. Warchoł T., Mostowska A., Lianeri M., et al. (2012). XRCC1 Arg399Gln Gene Polymorphism and the Risk of Systemic Lupus Erythematosus in the Polish Population. DNA and Cell Biology, 31(1), 50–56.
6. Blount S., Griffiths H., Emery P., et al. (1990). Reactive oxygen species modify human DNA, eliciting a more discriminating antigen for the diagnosis of systemic lupus erythematosus. Clin Exp Immunol, 81(3), 384–389.
7. Herrick A.L., Rafferty J.A., and Margison G.P. (1995). DNA repair deficiency in systemic lupus erythematosus; cause or consequence of disease and implications for management. Lupus, 4(6), 423–424.
8. McCurdy D., Tai L.Q., Frias S., et al. (1997). Delayed repair of DNA damage by ionizing radiation in cells from patients with juvenile systemic lupus erythematosus and rheumatoid arthritis. Radiat Res, 147(1), 48–54.
9. Takeda Y. and Dynan W.S. (2001). Autoantibodies against DNA double-strand break repair proteins. Front Biosci, 6, D1412-1422.
10. Lee K.-J., Dong X., Wang J., et al. (2002). Identification of Human Autoantibodies to the DNA Ligase IV/XRCC4 Complex and Mapping of an Autoimmune Epitope to a Potential Regulatory Region. The Journal of Immunology, 169(6), 3413–3421.
Antioxidants & Redox Signaling, 14(12), 2491–2507.
12. Hung R.J. (2005). Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review. American Journal of Epidemiology, 162(10), 925–942.
13. Caldecott K.W. (2003). XRCC1 and DNA strand break repair. DNA Repair (Amst), 2(9), 955–969.
14. Lindahl T. and Wood R.D. (1999). Quality control by DNA repair. Science,
286(5446), 1897–1905.
15. Batar B., Guven M., Onaran I., et al. (2010). DNA repair gene XRCC1 polymorphisms and the risk of asthma in a Turkish population. Allergy and Asthma Proceedings, 31(4), 349–354.
16. De Azevedo Silva J., Addobbati C., Sandrin-Garcia P., et al. (2014). Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations. Current Genomics, 15(1), 52–65.
17. Salimi S., Mohammadoo-khorasani M., Tabatabai E., et al. (2014). XRCC1
Arg399Gln and Arg194Trp Polymorphisms and Risk of Systemic Lupus Erythematosus in an Iranian Population: A Pilot Study. BioMed Research International, 2014, 1–5.
18. Jiang H., Wu D., Ma D., et al. (2013). Association between X-ray repair cross- complementation group 1 rs25487 polymorphism and pancreatic cancer risk.
Tumour Biol, 34(6), 3417–3421.
19. Cui Z., Yin Z., Li X., et al. (2012). Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta- analysis. BMC Cancer, 12, 71.
20. Wu H., Xu C., Chen G., et al. (2014). X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. J Gastroenterol Hepatol, 29(5), 926–933.
and adjuvant chemotherapy for breast cancer. Anticancer Res, 34(6), 3031– 3037.
22. Siegel M. and Lee S.L. (1973). The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum, 3(1), 1–54.
23. Pons-Estel G.J., Alarcón G.S., Scofield L., et al. (2010). Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 39(4), 257–268.
24. Chakravarty E.F., Bush T.M., Manzi S., et al. (2007). Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis & Rheumatism, 56(6), 2092–2094. 25. Uramoto K.M., Michet C.J., Thumboo J., et al. (1999). Trends in the incidence
and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum,
42(1), 46–50. (adsbygoogle = window.adsbygoogle || []).push({});
26. Petri M. (2002). Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol, 16(5), 847–858.
27. Symmons D.P.M. (1995). Occasional Series: Lupus Around the World Frequency of lupus in people of African origin. Lupus, 4(3), 176–178.
28. Carter E.E., Barr S.G., and Clarke A.E. (2016). The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nature Reviews Rheumatology, 12(10), 605–620.
29. Jakes R.W., Bae S.-C., Louthrenoo W., et al. (2012). Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care & Research, 64(2), 159–168.
30. Nguyễn Vĩnh Ngọc (2012). Lupus ban đỏ hệ thống. Bệnh học Nội khoa Tập 2. Nhà xuất bản Y học, 121–132.
32. Truedsson L., Sturfelt G., Johansen P., et al. (1995). Sharing of MHC haplotypes among patients with systemic lupus erythematosus from unrelated Caucasian multicase families: disease association with the extended haplotype [HLA-B8, SC01, DR17]. J Rheumatol, 22(10), 1852–1861.
33. Scofield R.H., Bruner G.R., Namjou B., et al. (2008). Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the X chromosome. Arthritis & Rheumatism, 58(8), 2511–2517.
34. Bernier M.-O., Mikaeloff Y., Hudson M., et al. (2009). Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum, 61(4), 476–481.
35. Leanos-Miranda A. (2006). Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology,
45(1), 97–101.
36. Jara-Quezada L., Graef A., and Lavalle C. (1991). Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol,
18(3), 349–353.
37. Mok C.C. and Lau C.S. (2000). Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus, 9(4), 252–257.
38. McMurray R.W. and May W. (2003). Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis & Rheumatism, 48(8), 2100–2110.
39. Bijl M. and Kallenberg C.G. (2006). Ultraviolet light and cutaneous lupus.
Lupus, 15(11), 724–727.
40. Caricchio R., McPhie L., and Cohen P.L. (2003). Ultraviolet B Radiation- Induced Cell Death: Critical Role of Ultraviolet Dose in Inflammation and Lupus Autoantigen Redistribution. The Journal of Immunology, 171(11), 5778– 5786.
16043–16056.
42. Rahman A. and Isenberg D.A. (2008). Systemic Lupus Erythematosus. New England Journal of Medicine, 358(9), 929–939.
43. Dooley M.A. (2016). Drug-Induced Lupus. Systemic Lupus Erythematosus. Elsevier, 473–479.
44. Petri M., Orbai A.-M., Alarcón G.S., et al. (2012). Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism, 64(8), 2677–2686. 45. Hochberg M.C. (1997). Updating the American college of rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 40(9), 1725–1725.
46. Tseng R.-C., Hsieh F.-J., Shih C.-M., et al. (2009). Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end- joining pathway genes: A multiple genotype-phenotype study. Cancer, 115(13), 2939–2948.
47. Hanssen-Bauer A., Solvang-Garten K., Akbari M., et al. (2012). X-Ray Repair Cross Complementing Protein 1 in Base Excision Repair. International Journal of Molecular Sciences, 13(12), 17210–17229.
48. Lindahl T. and Barnes D.E. (2000). Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol, 65, 127–133.
49. Araten D.J., Golde D.W., Zhang R.H., et al. (2005). A Quantitative Measurement of the Human Somatic Mutation Rate. Cancer Research, 65(18), 8111–8117.
50. Brookes A.J. (1999). The essence of SNPs. Gene, 234(2), 177–186.
51. Dowell D.R. (2015). NextGen genealogy: the DNA connection, LIBRARIES UNLIMITED, an imprint of ABC-CLIO, LLC, Santa Barbara, California.
53. Thomas P.E., Klinger R., Furlong L.I., et al. (2011). Challenges in the association of human single nucleotide polymorphism mentions with unique database identifiers. BMC Bioinformatics, 12(Suppl 4), S4.
54. Vidal A.E. (2001). XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. The EMBO Journal, 20(22), 6530–6539. (adsbygoogle = window.adsbygoogle || []).push({});
55. Monaco R., Rosal R., Dolan M.A., et al. (2007). Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J, 26(8), 541–546.
56. Sterpone S. and Cozzi R. (2010). Influence of XRCC1 Genetic Polymorphisms on Ionizing Radiation-Induced DNA Damage and Repair. Journal of Nucleic Acids, 2010, 1–6.
57. Brandt-Rauf P., Li Y., Long C., et al. (2009). Effect of the XRCC1 codon 399 polymorphism on the repair of vinyl chloride metabolite-induced DNA damage.
Journal of Carcinogenesis, 8(1), 14.
58. Beyer T.D., Kolowos W., Dumitriu I.E., et al. (2002). Apoptosis of the teratocarcinoma cell line Tera-1 leads to the cleavage of HERV-K10gag proteins by caspases and/or granzyme B. Scand J Immunol, 56(3), 303–309.
59. Mihara S., Suzuki N., Takeba Y., et al. (2002). Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Clin Exp Immunol, 129(2), 359–369.
60. van Bavel C.C., Dieker J.W., Tamboer W.P., et al. (2010). Lupus-derived monoclonal autoantibodies against apoptotic chromatin recognize acetylated conformational epitopes. Molecular Immunology, 48(1–3), 248–256.
HCC risk. Liver International, 31(6), 802–809.
62. Al Mutairi F.M., Alanazi M., Shalaby M., et al. (2013). Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients. Asian Pac J Cancer Prev, 14(6), 3809–3813.
63. Liu N., Fei X., Shen Y., et al. (2016). Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis.
Onco Targets Ther, 9, 579–586.
64. Saadat M., Pakyari N., and Farrashbandi H. (2008). Genetic polymorphism in the DNA repair gene XRCC1 and susceptibility to schizophrenia. Psychiatry Res, 157(1–3), 241–245.
65. Bazo A.P., Salvadori D., Salvadori R.A.F., et al. (2011). DNA repair gene polymorphism is associated with the genetic basis of atherosclerotic coronary artery disease. Cardiovasc Pathol, 20(1), e9-15.
66. Garibyan L. and Avashia N. (2013). Polymerase Chain Reaction. Journal of Investigative Dermatology, 133(3), 1–4.
67. Magdeldin S. (2012). Gel electrophoresis: principles and basics, InTech, Rijeka, Crotia.
68. Yang W., Kang X., Yang Q., et al. (2013). Review on the development of genotyping methods for assessing farm animal diversity. Journal of Animal Science and Biotechnology, 4(1), 2.
69. Lê Văn Phủng (2004). Giới thiệu kỹ thuật giải trình tự gen và real-time PCR. Tạp chí nghiên cứu khoa học, 32, 26–34.